Humanized CD19-directed CAR-T Cell Therapy in Pediatric Relapsed/Refractory Acute Lymphoblastic Leukemia With CNSL or Neurological Comorbidity
Overview
This clinical study evaluates humanized CD19 CAR-T cells in pediatric R/R ALL with CNS issues. Transduced T cells were cultured, amplified, and harvested over 5–7 days using the G-Rex® system.
What this paper found
Humanized CD19-directed CAR-T cells induced complete remission in children with relapsed/refractory acute lymphoblastic leukemia and central nervous system leukemia (CNSL) or neurological comorbidities, when tumor burden and neurological status were controlled before infusion. Among 12 prospectively treated patients (4 with CNSL, 3 with marrow relapse and comorbidity, 5 with marrow relapse alone), all 11 evaluable patients achieved complete remission on day 28 after one infusion of 1 × 10^6 CAR-T cells/kg. CAR-T cells were found in every cerebrospinal fluid sample on day 14, peaking at 39.5% of lymphocytes versus 16.2% in blood, and persisted there a median 5.5 months in CNSL versus 3 months in isolated marrow relapse. One patient with comorbidity whose marrow blasts were not reduced died of neurotoxicity; one-year event-free survival was 90.9%.
Note: Small cohort of 12 patients; the authors note that the number of patients was too small to analyze correlations between marrow tumor burden and neurotoxicity risk.
CAR-T can be given safely and effectively to pediatric patients with R/R ALL with CNSL or NC who have near-normal neurological status. — Na Zhang, Jingbo Shao, Hong Li, Jiashi Zhu, Min Xia, Kai Chen, Hui Jiang, Journal of Immunotherapy
Study details
- Authors
- Na Zhang, Jingbo Shao, Hong Li, Jiashi Zhu, Min Xia, Kai Chen, Hui Jiang
- Institution
- Department of Hematology and Oncology, Shanghai Children's Hospital, School of Medicine, Shanghai Jiao Tong University, Shanghai, China · Department of Clinical Laboratory, Shanghai Children's Hospital, School of Medicine, Shanghai Jiao Tong University, Shanghai, China
- Journal
- Journal of Immunotherapy
- Year
- 2022
- Cell type(s)
- CAR T Cells
- Application area
- Hematologic malignancy
How G-Rex® was used
Peripheral blood mononuclear cells were collected by apheresis, and T cells were activated with anti-CD3/anti-CD28 beads for 24–48 hours, cultured in X-Vivo 15 medium with 200 IU/ml rhIL-2, and transduced for 48 hours with a lentiviral humanized CD19 CAR vector. The transduced T cells were then cultured, expanded and harvested over 5–7 days in the G-Rex® system, with manufacturing performed by Shanghai Genbase Biotechnology. The products had a mean CAR transduction efficiency of 54.1% and were infused at a single dose of 1 × 10^6 CAR-T cells/kg.
Explore related
Full citation
Zhang N, Shao J, Li H, et al. Humanized CD19-directed CAR-T Cell Therapy in Pediatric Relapsed/Refractory Acute Lymphoblastic Leukemia With CNSL or Neurological Comorbidity. J Immunother. 2022;45(9):396-406.
Building a similar workflow?
Talk to a ScaleReady specialist about how the G-Rex® platform can support your program — from process development to clinical-scale manufacturing.